Contact Information: Contacts: MDRNA, Inc.: Mark Bales, Ph.D. IP Counsel (425) 908-3634 mbales@mdrnainc.com Westwicke Partners (Investors): Stefan Loren, Ph.D. (443) 213-0507 sloren@westwicke.com John Woolford (443) 213-0506 john.woolford@westwicke.com McKinney|Chicago (Media): Alan Zachary (312) 944-6784 x 316 (708) 707-6834 azachary@mckinneychicago.com
MDRNA, Inc. Issued Patent for the Use of Nucleic Acids to Treat Cancer
MDRNA IP Estate Extends Into Asia
| Source: MDRNA, Inc
BOTHELL, WA--(Marketwire - January 26, 2010) - MDRNA, Inc. (NASDAQ : MRNA ), a leading
RNAi-based drug discovery and development company, today announced that the
State Intellectual Property Office of the People's Republic of China (PRC)
has issued a Notification of Granting Patent Rights for PRC 200480018784
which includes the use of nucleic acids, e.g., an siRNA, for the treatment
of cancer. The patent describes modulation of claudins, which are proteins
implicated in tumor progression and metastasis.
"China's pharmaceutical markets are growing nearly 20% a year," said J.
Michael French, President and CEO of MDRNA. "China has seen significant
expansion in both the pharmaceutical and biotech sectors, which provides an
ideal environment for our ongoing efforts to seek international R&D
collaborations and investment opportunities. With this patent and our
recent allowance of a patent covering RNAi-based modulation of JAM-1 for
the treatment of cancer we continue to extend our oncology patent estate
worldwide."
About MDRNA's Technology
MDRNA has a broad intellectual property estate that encompasses four key
RNAi technology platforms: siRNA constructs, chemistry, nucleic acid
delivery, and gene targets. The MDRNA-owned siRNA constructs and chemistry
include its proprietary UsiRNA construct, which is a duplex siRNA
chemically modified with non-nucleotide acyclic monomers (UNAs), and is
distinct from the standard siRNA construct used by others in the industry.
UsiRNAs are fully recognized by the RNAi machinery and provide for potent
RNAi activity while specific placement of UNAs in a duplex siRNA minimizes
potential off-target effects by the guide strand and reduces undesired
passenger strand activity. Furthermore, UsiRNAs escape the surveillance
mechanisms associated with cytokine induction, and provide protection from
nuclease degradation.
The MDRNA delivery platforms include DiLA2 and nanoparticle forming
peptides. DiLA2 is an MDRNA proprietary delivery platform of novel synthetic
di-alkylated amino acid compounds used to make liposomal delivery
formulations. The DiLA2 platform enables MDRNA to tailor the charge, linker
and acyl chains of amino acids in order to configure liposomes for delivery
to target tissues of interest. In addition, the platform is designed to
permit attachment of various peptides and other targeting molecules to
improve a variety of delivery characteristics. The MDRNA peptide
nanoparticle platform includes exclusively in-licensed and developed IP
surrounding the use of peptides for nanoparticle formulations that increase
cellular uptake and endosomal release of siRNAs. MDRNA is currently
biopanning its patented phage display library to identify additional
peptides for targeted delivery, cellular uptake and endosomal release of
siRNA.
MDRNA owns or controls 7 issued or allowed patents, and has more than 40
pending patent applications, 126 pending foreign patent applications and 6
PCT applications.
About MDRNA, Inc.
MDRNA is a biotechnology company focused on the development and
commercialization of therapeutic products based on RNA interference (RNAi).
Our goal is to improve human health through the development of RNAi-based
compounds and drug delivery technologies that together provide superior
therapeutic options for patients. Over the past decade, we have developed
substantial capabilities in molecular biology, cellular biology, lipid
chemistry, peptide chemistry, pharmacology and bioinformatics, which we are
applying to a wide range of RNAi technologies and delivery approaches.
These capabilities plus the in-licensing of key RNAi-related intellectual
property have rapidly enabled us to become a leading RNAi-based
therapeutics company with a pre-clinical pipeline in oncology. Through our
capabilities, expertise and know-how, we are incorporating multiple RNAi
technologies as well as peptide- and lipid-based delivery approaches into a
single integrated drug discovery platform that will be the engine for our
clinical pipeline as well as a versatile platform for establishing broad
therapeutic partnerships with biotechnology and pharmaceutical companies.
We are also investing in new technologies that we expect to lead to safer
and more effective RNAi-based therapeutics while aggressively building upon
our broad and extensive intellectual property estate. By combining broad
expertise in siRNA science with proven delivery platforms and a strong IP
position, MDRNA is well positioned as a leading RNAi-based drug discovery
and development company. Additional information about MDRNA, Inc. is
available at http://www.mdrnainc.com.
MDRNA Forward-Looking Statements
Statements made in this news release may be forward-looking statements
within the meaning of Federal Securities laws that are subject to certain
risks and uncertainties and involve factors that may cause actual results
to differ materially from those projected or suggested. Factors that could
cause actual results to differ materially from those in forward-looking
statements include, but are not limited to: (i) the ability of MDRNA to
obtain additional funding; (ii) the ability of MDRNA to attract and/or
maintain manufacturing, research, development and commercialization
partners; (iii) the ability of MDRNA and/or a partner to successfully
complete product research and development, including preclinical and
clinical studies and commercialization; (iv) the ability of MDRNA and/or a
partner to obtain required governmental approvals; and (v) the ability of
MDRNA and/or a partner to develop and commercialize products that can
compete favorably with those of competitors. Additional factors that could
cause actual results to differ materially from those projected or suggested
in any forward-looking statements are contained in MDRNA's most recent
periodic reports on Form 10-K and Form 10-Q that are filed with the
Securities and Exchange Commission. MDRNA assumes no obligation to update
and supplement forward-looking statements because of subsequent events.